Mainz Biomed Works To Ensure Early Cancer Detection W/ 90% 5 Year Survival By Improving Test Access

Benzinga

Advanced Screening Equals Early Detection: Cancer screening has to be simple, readily available, and affordable to be effective, which is where Mainz Biomed comes in. The molecular genetics diagnostic company specializing in the early detection of cancer is revolutionizing the colorectal cancer testing industry with ColoAlert, its flagship product.

Transcript

00:00Great news in the global fight against cancer.

00:04The innovative biotech company,

00:06Mines Biomed, trading on the NASDAQ as MYNZ,

00:09has released data from a recent study that shows

00:12promising results in two key areas

00:14for early detection of certain cancers.

00:17Early detection is critical to

00:18successful outcomes for cancer patients.

00:20It can mean the difference between life and death.

00:22The company presented the data from

00:24its early detect study at

00:26Digestive Disease Week 2024 in Washington, DC.

00:29The study, which was conducted across

00:3121 specialized gastroenterology sites in the US,

00:34and included 254 clinical patients,

00:37showcases a comprehensive approach to early cancer detection,

00:41particularly colorectal cancer, CRC.

00:43The multimodal screening test developed by Mines Biomed

00:46integrates a fecal immunochemical test,

00:49DNA and mRNA biomarkers,

00:51and a proprietary artificial intelligence,

00:54AI, machine learning algorithm.

00:56This innovative test is capable of distinguishing

00:58between various conditions,

01:00including colorectal cancer, CRC,

01:03and advanced adenomas, AA, non-advanced adenomas,

01:07and samples with no findings.

01:10The study results highlight the test's efficacy

01:12in accurately identifying biomarkers

01:14and enhancing early detection rates for CRC

01:17and significant precancerous conditions.

01:19By focusing on this dual approach

01:21of combining biomarker analysis with AI,

01:24Mines Biomed aims to improve screening practices,

01:27shifting from cancer detection

01:28to prevention,

01:29and ultimately reducing cancer mortality rates globally.

01:33The detailed presentation at DDW 2024

01:36delved into the test's performance

01:38and its potential impact

01:39on current colorectal cancer screening methodologies.

01:42The resulting data shows that Mines' test

01:44is in line with the leading tests on the market

01:46for colorectal cancer

01:48and significantly improves the detection

01:50of advanced adenomas.

Category

Transcript

Recommended